Biodesix announces first four private payer coverage policies for the nodify xl2® test

Boulder, colo.--( business wire )--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced positive coverage decisions from four private payers including blue cross blue shield of north carolina, blue cross blue shield of south carolina, blue cross blue shield of kansas city, and capital district physician's health plan (cdphp) of new york, all effective fourth quarter 2022. biodesix's nodify xl2® test will now be covered for more than 2.3 million enrollees of blue cross of north carolina, 1.2 million enrollees of blue cross blue shield of south carolina, 0.5 million enrollees from blue cross blue shield of kansas city, and 0.4 million enrollees of cdphp across new york state.
BDSX Ratings Summary
BDSX Quant Ranking